TRPV1 inhibition sensitizes tumors to PD-1 blockade by reversing resistance to CTL-mediated killing



Summary

TRPV1 inhibition can enhance the effectiveness of PD-1 blockade immunotherapy in treating tumors. Tumors can develop resistance to cytotoxic T lymphocyte (CTL)-mediated killing, a key mechanism of PD-1 blockade. Studies reveal that blocking TRPV1, a pain receptor, reverses this resistance, making tumors more susceptible to CTL attack. By modulating the tumor microenvironment and promoting immune cell infiltration, TRPV1 inhibition sensitizes tumors to the effects of PD-1 blockade. This suggests that combining TRPV1 inhibitors with PD-1 blockade could offer a more effective therapeutic approach for cancers that are otherwise resistant to immunotherapy.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!